Feb 3 2011
Probi has signed an agreement giving Ta`am Teva Altman rights to launch Probi's dietary supplement for gut health based on Lp299v™ in Israel. The launch is planned to take place in the second quarter of 2011.
"Ta`am Teva Altman is one of the leaders in consumer healthcare in Israel and the company is also well-known internationally. I am particularly pleased that we are able to move quickly to launch," says Michael Oredsson, CEO of Probi.
The Israeli VMS market is estimated at 200 million US dollars and is expected to have an annual growth of approximately 10 percent.
Dietary supplements based on Probi's probiotics are sold or are in the process of being launched in more than 40 countries worldwide.
The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.